BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

...response letter for NASH candidate Ocaliva obeticholic acid (see “NASH Pipeline Still Full”).Santhera all-in on Idorsia’s...
...exclusively in-license worldwide rights to Duchenne muscular dystrophy therapy vamorolone from Idorsia Ltd. (SIX:IDIA) (see “Deal with Idorsia...
...Inc. Kite Pharma Inc. HiFiBiO Therapeutics Amarin Corp. plc Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals plc Intercept Pharmaceuticals Inc. Santhera Pharmaceuticals Holding AG Idorsia Ltd. Pfizer...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...an anti-CD25 mAb and a pyrrolobenzodiazepine dimer payload. Idorsia notches second win for insomnia therapy Idorsia Ltd....
...member 7 BioCentury Staff BLU-5937, neo5937 Linzagolix (KLH-2109, OBE2109) Cami-T, HuMax-TAC-ADC, camidanlumab tesirine (ADCT-301) daridorexant (ACT-541468) UCARTCS1 Bellus Health Inc. ObsEva S.A. ADC Therapeutics S.A. Idorsia Ltd. Boehringer...
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

...last fall showed signs of efficacy. Clinical readouts last fall from AstraZeneca plc (LSE:AZN; NYSE:AZN), Idorsia Ltd....
BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

...pleural mesothelioma. Idorsia’s daridorexant meets in Phase III for insomnia Top-line Phase III results from Idorsia Ltd....
...data from another Phase III trial of the OX1R/OX2R dual antagonist for insomnia in 3Q20. Idorsia...
...parathyroid hormone VP30 - Ebola virus VP30 BioCentury Staff bempedoic acid/ezetimibe Regeneron Pharmaceuticals Inc. Galapagos N.V. Bristol Myers Squibb Co. Idorsia Ltd. Ascendis...
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

...the rare metabolic disease space, having worked on programs at Actelion Ltd. and its successor Idorsia...
BioCentury | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

...of a high placebo effect and inconsistencies in standard of care. AstraZeneca plc (LSE:AZN; NYSE:AZN), Idorsia Ltd....
...AZ’s Phase III compound anifrolumab is a mAb that targets the type I interferon receptor; Idorsia’s...
...biomarkers for patient stratification in lupus trials (see “DxTerity Biomarker Bolsters Lupus Patient Stratification” ). Idorsia...
BioCentury | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

...for Rheumatology Professionals (ARP) annual meeting this week, SLE candidates from AstraZeneca plc (LSE:AZN; NYSE:AZN), Idorsia Ltd....
...lupus trials (see “DxTerity Biomarker Bolsters Lupus Patient Stratification” ). In its Phase II trial, Idorsia...
...the standard SLE patient questionnaires, which may intensify the placebo effect. Once daily dosing of Idorsia’s...
BioCentury | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

...completed enrollment, the farnesyl transferase inhibitor led to an interim overall response rate of 38%. Idorsia's...
...selatogrel shows rapid platelet aggregation inhibition At the European Society of Cardiology Congress in Paris, Idorsia Ltd....
...Janus kinase Sandi Wong and Hongjiang Li, Staff Writers Aerucin (AR-105) CTP-543 PB-718 selatogrel (ACT-246475) tipifarnib (zarnestra, R115777) Aridis Pharmaceuticals Inc. Concert Pharmaceuticals Inc. Idorsia Ltd. Kura...
BioCentury | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

...$20 million in upfront cash, plus an equity stake making Idorsia Ltd. (SIX:IDIA) its majority shareholder. Idorsia...
...from ReveraGen via a sublicense when it spun out of Actelion Ltd. (see "Deal With Idorsia...
...optimistic and expect a decision by CHMP around mid-2020," the spokesperson added. Mary Romeo, Assistant Editor Vamorolone (VBP15) Idorsia Ltd. ReveraGen...
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...III trial. Phase II insomnia data from Idorsia At the SLEEP meeting in San Antonio, Idorsia Ltd....
...obinutuzumab (Generic) Molgradex nemorexant (ACT-541468) NKTR-358 RSLV-132 SEL-212 Tradjenta, Trajenta, Trazenta, linagliptin (BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli Lilly and Co. Follica Inc. Idorsia Ltd. Nektar...
Items per page:
1 - 10 of 40
BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

...response letter for NASH candidate Ocaliva obeticholic acid (see “NASH Pipeline Still Full”).Santhera all-in on Idorsia’s...
...exclusively in-license worldwide rights to Duchenne muscular dystrophy therapy vamorolone from Idorsia Ltd. (SIX:IDIA) (see “Deal with Idorsia...
...Inc. Kite Pharma Inc. HiFiBiO Therapeutics Amarin Corp. plc Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals plc Intercept Pharmaceuticals Inc. Santhera Pharmaceuticals Holding AG Idorsia Ltd. Pfizer...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...an anti-CD25 mAb and a pyrrolobenzodiazepine dimer payload. Idorsia notches second win for insomnia therapy Idorsia Ltd....
...member 7 BioCentury Staff BLU-5937, neo5937 Linzagolix (KLH-2109, OBE2109) Cami-T, HuMax-TAC-ADC, camidanlumab tesirine (ADCT-301) daridorexant (ACT-541468) UCARTCS1 Bellus Health Inc. ObsEva S.A. ADC Therapeutics S.A. Idorsia Ltd. Boehringer...
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

...last fall showed signs of efficacy. Clinical readouts last fall from AstraZeneca plc (LSE:AZN; NYSE:AZN), Idorsia Ltd....
BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

...pleural mesothelioma. Idorsia’s daridorexant meets in Phase III for insomnia Top-line Phase III results from Idorsia Ltd....
...data from another Phase III trial of the OX1R/OX2R dual antagonist for insomnia in 3Q20. Idorsia...
...parathyroid hormone VP30 - Ebola virus VP30 BioCentury Staff bempedoic acid/ezetimibe Regeneron Pharmaceuticals Inc. Galapagos N.V. Bristol Myers Squibb Co. Idorsia Ltd. Ascendis...
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

...the rare metabolic disease space, having worked on programs at Actelion Ltd. and its successor Idorsia...
BioCentury | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

...of a high placebo effect and inconsistencies in standard of care. AstraZeneca plc (LSE:AZN; NYSE:AZN), Idorsia Ltd....
...AZ’s Phase III compound anifrolumab is a mAb that targets the type I interferon receptor; Idorsia’s...
...biomarkers for patient stratification in lupus trials (see “DxTerity Biomarker Bolsters Lupus Patient Stratification” ). Idorsia...
BioCentury | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

...for Rheumatology Professionals (ARP) annual meeting this week, SLE candidates from AstraZeneca plc (LSE:AZN; NYSE:AZN), Idorsia Ltd....
...lupus trials (see “DxTerity Biomarker Bolsters Lupus Patient Stratification” ). In its Phase II trial, Idorsia...
...the standard SLE patient questionnaires, which may intensify the placebo effect. Once daily dosing of Idorsia’s...
BioCentury | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

...completed enrollment, the farnesyl transferase inhibitor led to an interim overall response rate of 38%. Idorsia's...
...selatogrel shows rapid platelet aggregation inhibition At the European Society of Cardiology Congress in Paris, Idorsia Ltd....
...Janus kinase Sandi Wong and Hongjiang Li, Staff Writers Aerucin (AR-105) CTP-543 PB-718 selatogrel (ACT-246475) tipifarnib (zarnestra, R115777) Aridis Pharmaceuticals Inc. Concert Pharmaceuticals Inc. Idorsia Ltd. Kura...
BioCentury | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

...$20 million in upfront cash, plus an equity stake making Idorsia Ltd. (SIX:IDIA) its majority shareholder. Idorsia...
...from ReveraGen via a sublicense when it spun out of Actelion Ltd. (see "Deal With Idorsia...
...optimistic and expect a decision by CHMP around mid-2020," the spokesperson added. Mary Romeo, Assistant Editor Vamorolone (VBP15) Idorsia Ltd. ReveraGen...
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...III trial. Phase II insomnia data from Idorsia At the SLEEP meeting in San Antonio, Idorsia Ltd....
...obinutuzumab (Generic) Molgradex nemorexant (ACT-541468) NKTR-358 RSLV-132 SEL-212 Tradjenta, Trajenta, Trazenta, linagliptin (BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli Lilly and Co. Follica Inc. Idorsia Ltd. Nektar...
Items per page:
1 - 10 of 40